Investment
Features
FeesSafety
Academy
More
Pluang+

Compare UiPath Inc (PATH) vs Teladoc Health Inc (TDOC) Price & Performance

UiPath IncTrade
Teladoc Health IncTrade

Price performance (Past 24H)

Key statistics

UiPath Inc vs Teladoc Health Inc — how do they compare? UiPath Inc trades at $13.46 (market cap $6.91B), while Teladoc Health Inc trades at $5.62 (market cap $1.01B). The key difference: UiPath Inc is far larger — about 6.8× Teladoc Health Inc's market cap, and UiPath Inc is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Teladoc Health Inc for 39 Days on average.

PATHTDOC
Market Cap
$6.91B$1.01B
Volume
34,321,2504,668,477
Sector
TechnologyHealth
52-Week High
$19.29$9.72
52-Week Low
$9.38$4.47
Typical Hold Time
139 Days39 Days
Enterprise Value
$5.70B$1.27B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

UiPath Inc

UiPath (PATH) trades at $13.07, down 0.23% with bearish technical signals despite strong fundamentals. The company shows improving financials with revenue growth from $1.43B in 2025 to projected $1.7B in 2026, transitioning to profitability with a 21.03% net margin. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though technical indicators show resistance at $13 with RSI suggesting mixed momentum.

PATH offers compelling value with a P/E of 19.78 and analyst consensus target of $15.13 (16% upside), but faces execution risks and competitive pressure. The stock's bearish technical setup contrasts with fundamental improvement, creating potential for volatility. Investors should weigh strong profitability metrics against recent price weakness and mixed analyst sentiment.

Teladoc Health Inc

Teladoc Health (TDOC) trades at $5.56, down 3.64% on the day, reflecting persistent bearish technical signals and negative earnings. The stock shows weak profitability with a net income margin of -7.13% and negative ROE, though valuation ratios like P/S of 0.4 and EV/EBITDA of 5.89 appear low. Recent news includes a CFO transition and ongoing investor investigations, adding to uncertainty.

The outlook remains challenging due to consecutive net losses and competitive pressures, but the consensus price target of $8.83 suggests potential upside if operational improvements materialize. Key risks include sustained unprofitability, high debt levels, and weak sentiment, requiring careful monitoring of cost management and revenue stabilization efforts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PATH
47% Buy53% Sell
Avg holding period · 139 Days
TDOC

No sentiment data available yet.

About UiPath Inc

UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.

Read more on PATH →

About Teladoc Health Inc

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.

Read more on TDOC →